Shortly before I went on "hiatus" last year, I posted about the Nobel given for "directed evolution" and what I casually referred to as "Mubabs" - you know - all those newfangled biologic medicines that have become pervasive mainstays of broadcast and print advertising. I thought it was amusing just how many oddly named mubabs there were and began collecting the oddly named drugs and what they were prescribed for summer before last.
reportlinker | The biologics industry comprises companies manufacturing biological
products that are derived from genetically modified proteins and human
genes.Biologics products include a wide range of recombinant therapeutic
proteins, vaccines, and monoclonal antibodies.
These products are isolated from natural sources such as human, animal, and microorganisms by biotechnological methods and other cutting-edge technologies.
Executive Summary
The global biologics market was worth $221 billion in 2017 and is essentially segmented into monoclonal antibodies, therapeutic proteins and vaccines. Biologics are very large complex molecules manufactured in a living system such as microorganisms, animal cells or plant cells. They are produced using the recombinant DNA technology and are composed of sugars, proteins, nucleic acids or a combination of these substances. In 2017, 12 biologics were approved in the USA, 10 in European Union and 7 in Japan. There are over 1000 biologics under development which will drive the biologics market in the future. Cancer is the therapeutic area with maximum number of biologics under development and Alzheimer’s has the least number.
Of the total biologics market across the globe, Monoclonal antibodies (mAbs) accounted for a share of 43% in 2017 and was worth $94 billion. North America had the highest share in 2017 at $39.2 billion followed by Western Europe with a market value of $26.4 billion. Asia-Pacific was the third largest market with a share of 12% and a market value of $11.4 billion. mAbs are biological drugs that recognize and bind to a specific antigen that causes various chronic health conditions such as arthritis, cancer, multiple sclerosis. mAbs can be further segmented based on the presence of different amounts of murine (mouse or rat origin) sequences in the variable region. The segments consist of murine mAbs, chimeric mAbs, human and humanized mAbs. Of these, humanized mAbs accounted for 43% share in the monoclonal antibody market with a market value of $37.6 billion followed by human mAbs and chimeric mAbs at $32.9 billion and $18.8 billion respectively. Murine mAbs accounted only for 5% of the total mAbs market and was worth $4.7 billion in 2017.
Therapeutic proteins or recombinant proteins are engineered in the laboratory and works by targeting therapeutic process which compensates for the deficiency of an essential protein. Therapeutic proteins include cytokines, peptide hormones and enzymes. The market for therapeutic protein was worth $80 billion in 2017 accounting for a share of 36% of the global biologics market. North American market for therapeutic proteins was worth $33 billion in 2017 followed by Western Europe at $17.3 billion. The market in Asia Pacific was worth $11.3 billion and the markets in South America, Eastern Europe, Middle East and Africa accounted only for 4%, 6%, 9% and 4% respectively. Based on the segmentation of therapeutic proteins into cytokines, peptide hormones and enzymes, peptide hormones accounted for 45% of the market followed by cytokines at 18% and enzymes at 10% share. Other blood factors also had a share of around 27% in the total therapeutic proteins market globally.
These products are isolated from natural sources such as human, animal, and microorganisms by biotechnological methods and other cutting-edge technologies.
Executive Summary
The global biologics market was worth $221 billion in 2017 and is essentially segmented into monoclonal antibodies, therapeutic proteins and vaccines. Biologics are very large complex molecules manufactured in a living system such as microorganisms, animal cells or plant cells. They are produced using the recombinant DNA technology and are composed of sugars, proteins, nucleic acids or a combination of these substances. In 2017, 12 biologics were approved in the USA, 10 in European Union and 7 in Japan. There are over 1000 biologics under development which will drive the biologics market in the future. Cancer is the therapeutic area with maximum number of biologics under development and Alzheimer’s has the least number.
Of the total biologics market across the globe, Monoclonal antibodies (mAbs) accounted for a share of 43% in 2017 and was worth $94 billion. North America had the highest share in 2017 at $39.2 billion followed by Western Europe with a market value of $26.4 billion. Asia-Pacific was the third largest market with a share of 12% and a market value of $11.4 billion. mAbs are biological drugs that recognize and bind to a specific antigen that causes various chronic health conditions such as arthritis, cancer, multiple sclerosis. mAbs can be further segmented based on the presence of different amounts of murine (mouse or rat origin) sequences in the variable region. The segments consist of murine mAbs, chimeric mAbs, human and humanized mAbs. Of these, humanized mAbs accounted for 43% share in the monoclonal antibody market with a market value of $37.6 billion followed by human mAbs and chimeric mAbs at $32.9 billion and $18.8 billion respectively. Murine mAbs accounted only for 5% of the total mAbs market and was worth $4.7 billion in 2017.
Therapeutic proteins or recombinant proteins are engineered in the laboratory and works by targeting therapeutic process which compensates for the deficiency of an essential protein. Therapeutic proteins include cytokines, peptide hormones and enzymes. The market for therapeutic protein was worth $80 billion in 2017 accounting for a share of 36% of the global biologics market. North American market for therapeutic proteins was worth $33 billion in 2017 followed by Western Europe at $17.3 billion. The market in Asia Pacific was worth $11.3 billion and the markets in South America, Eastern Europe, Middle East and Africa accounted only for 4%, 6%, 9% and 4% respectively. Based on the segmentation of therapeutic proteins into cytokines, peptide hormones and enzymes, peptide hormones accounted for 45% of the market followed by cytokines at 18% and enzymes at 10% share. Other blood factors also had a share of around 27% in the total therapeutic proteins market globally.
0 comments:
Post a Comment